ArticleScience translational medicine2026

Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer.

Julie R Duffield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.